Praxis Precision Medicines (PRAX) Interest Expenses (2019 - 2026)

Praxis Precision Medicines' Interest Expenses history runs 8 years deep, the most recent figure standing at $454.1 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 40551.3% year-over-year to $454.1 million in Q1 2026; TTM through Mar 2026 was $454.1 million, a 40551.3% increase from a year earlier, with the FY2025 full-year figure at $409.9 million, up 87.78% from the prior year.
• Interest Expenses advanced to $454.1 million in Q1 2026 per PRAX's latest filing, from $306.6 million in the prior quarter.
• Across five years, Interest Expenses topped out at $454.1 million in Q1 2026 and bottomed at $23000.0 in Q1 2023.
• The 5-year median for Interest Expenses is $8.7 million (2025), against an average of $79.9 million.
• Across the five-year window, Interest Expenses sank 99.84% in 2023 and jumped 61626.09% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $143.9 million in 2022, then advanced by 25.41% to $180.5 million in 2023, then increased by 20.94% to $218.3 million in 2024, then jumped by 40.45% to $306.6 million in 2025, then soared by 48.1% to $454.1 million in 2026.
• Per Business Quant, the three latest PRAX Interest Expenses figures stand at $454.1 million (Q1 2026), $306.6 million (Q4 2025), and $8.7 million (Q3 2025).